These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15743210)

  • 1. Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist.
    Chauvignac C; Miller CN; Srivastava SK; Lewis JW; Husbands SM; Traynor JR
    J Med Chem; 2005 Mar; 48(5):1676-9. PubMed ID: 15743210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2007 May; 50(9):2254-8. PubMed ID: 17407276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
    Srivastava SK; Shefali S; Miller CN; Aceto MD; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2004 Dec; 47(26):6645-8. PubMed ID: 15588100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
    Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
    Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
    J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.
    Williams DA; Zheng Y; David BG; Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Selley DE; Dewey WL; Akbarali HI; Zhang Y
    ACS Chem Neurosci; 2016 Aug; 7(8):1120-9. PubMed ID: 27269866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
    Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
    J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
    Wang D; Sun X; Sadee W
    J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
    Broom DC; Guo L; Coop A; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1195-200. PubMed ID: 10945877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
    Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
    J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes.
    Daniels DJ; Kulkarni A; Xie Z; Bhushan RG; Portoghese PS
    J Med Chem; 2005 Mar; 48(6):1713-6. PubMed ID: 15771416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
    Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
    Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
    Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.
    Harland AA; Pogozheva ID; Griggs NW; Trask TJ; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2017 Nov; 8(11):2549-2557. PubMed ID: 28796483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid activity of spinally selective analogues of N-naphthoyl-β-naltrexamine in HEK-293 cells and mice.
    Le Naour M; Lunzer MM; Powers MD; Portoghese PS
    J Med Chem; 2012 Jan; 55(2):670-7. PubMed ID: 22136373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
    Lester PA; Traynor JR
    Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons.
    Jamshidi RJ; Sullivan LC; Jacobs BA; Chavera TA; Berg KA; Clarke WP
    J Pharmacol Exp Ther; 2016 Nov; 359(2):319-328. PubMed ID: 27605628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.